ATE532786T1 - Spirobenzazepine als vasopressinantagonisten - Google Patents

Spirobenzazepine als vasopressinantagonisten

Info

Publication number
ATE532786T1
ATE532786T1 AT07842799T AT07842799T ATE532786T1 AT E532786 T1 ATE532786 T1 AT E532786T1 AT 07842799 T AT07842799 T AT 07842799T AT 07842799 T AT07842799 T AT 07842799T AT E532786 T1 ATE532786 T1 AT E532786T1
Authority
AT
Austria
Prior art keywords
renal
hyponatremia
hypertension
insufficiency
formula
Prior art date
Application number
AT07842799T
Other languages
English (en)
Inventor
Min A Xiang
Mona Patel
Philip Rybczynski
Joseph Gunnet
Keith T Demarest
Richard Look
Bruce Maryanoff
Michael J Costanzo
Stephen C Yabut
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE532786T1 publication Critical patent/ATE532786T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT07842799T 2006-09-22 2007-09-19 Spirobenzazepine als vasopressinantagonisten ATE532786T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82665406P 2006-09-22 2006-09-22
PCT/US2007/078917 WO2008036755A1 (en) 2006-09-22 2007-09-19 Spiro benzazepines used as vasopressin antagonists

Publications (1)

Publication Number Publication Date
ATE532786T1 true ATE532786T1 (de) 2011-11-15

Family

ID=39030853

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07842799T ATE532786T1 (de) 2006-09-22 2007-09-19 Spirobenzazepine als vasopressinantagonisten

Country Status (14)

Country Link
US (1) US7825110B2 (de)
EP (1) EP2078022B1 (de)
JP (1) JP2010504351A (de)
CN (1) CN101541806A (de)
AT (1) ATE532786T1 (de)
AU (1) AU2007299818B2 (de)
CA (1) CA2665849A1 (de)
CY (1) CY1112270T1 (de)
DK (1) DK2078022T3 (de)
ES (1) ES2374582T3 (de)
PL (1) PL2078022T3 (de)
PT (1) PT2078022E (de)
SI (1) SI2078022T1 (de)
WO (1) WO2008036755A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013057944A1 (ja) * 2011-10-19 2013-04-25 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
CA2955071A1 (en) 2014-07-15 2016-01-21 Grunenthal Gmbh Substituted azaspiro(4.5)decane derivatives
WO2017006968A1 (ja) 2015-07-07 2017-01-12 日本たばこ産業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン誘導体の製造方法及びその中間体
TWI816651B (zh) 2016-12-21 2023-10-01 日商日本煙草產業股份有限公司 7H-吡咯并[2,3-d]嘧啶衍生物的製造方法及其合成中間體
CN111295373A (zh) 2017-09-15 2020-06-16 阿泽凡药物公司 用于治疗脑损伤的组合物和方法
EP3740236A1 (de) 2018-01-16 2020-11-25 Bayer Aktiengesellschaft Unterstützung bei der behandlung von herzinsuffizienz
EP4253367A1 (de) * 2020-11-26 2023-10-04 Shanghai Jemincare Pharmaceuticals Co., Ltd. Neuartiges benzazepinspiroderivat
CN112939864B (zh) * 2021-01-29 2022-05-06 中国医科大学 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
KR0167349B1 (ko) 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
US5985869A (en) 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
CA2143117A1 (en) 1992-10-07 1994-04-14 Ben E. Evans Tocolytic oxytocin receptor antagonists
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
DK1307430T3 (da) 2000-07-05 2006-01-30 Ortho Mcneil Pharm Inc Ikke-peptidsubstituerede spirobenzoazepiner som vasopressin-antagonister
AU2002231098A1 (en) * 2000-12-15 2002-06-24 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
US7011898B2 (en) * 2003-03-21 2006-03-14 Air Products And Chemicals, Inc. Method of joining ITM materials using a partially or fully-transient liquid phase
CA2529513A1 (en) 2003-06-17 2005-01-06 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
CA2529649C (en) 2003-06-17 2012-01-31 Janssen Pharmaceutica N.V. Substituted spirobenzazepines
EP1984342A2 (de) 2006-01-20 2008-10-29 Janssen Pharmaceutica, N.V. NEUE FESTE FORMEN VON (4R)-1-[4-(2-CHLOR-5-FLUORBENZOYL)AMINO-3-METHOXYBENZOYL]-1,2,3,5-TETRAHYDRO-SPIRO[4H-1-BENZAZEPIN-4,1ý-[2]CYCLOPENTEN]-3ý-CARBONSÄURE

Also Published As

Publication number Publication date
AU2007299818B2 (en) 2012-08-02
ES2374582T3 (es) 2012-02-20
EP2078022A1 (de) 2009-07-15
PT2078022E (pt) 2012-01-11
US20080076753A1 (en) 2008-03-27
PL2078022T3 (pl) 2012-04-30
DK2078022T3 (da) 2012-02-13
CN101541806A (zh) 2009-09-23
SI2078022T1 (sl) 2012-01-31
WO2008036755A1 (en) 2008-03-27
AU2007299818A1 (en) 2008-03-27
CY1112270T1 (el) 2015-12-09
US7825110B2 (en) 2010-11-02
CA2665849A1 (en) 2008-03-27
EP2078022B1 (de) 2011-11-09
JP2010504351A (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
CY1112270T1 (el) Σπειρο βενζαζεπινες χρησιμες ως ανταγωνιστες αγγειοπιεσινης
MA33358B1 (fr) Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
MY128065A (en) Tricyclic benzodiazepines as vasopressin receptor antagonists
EA200900811A1 (ru) Имидазолы в качестве ингибиторов альдостеронсинтазы
EA201070339A1 (ru) Активаторы растворимой гуанилатциклазы
HN2008001374A (es) Compuestos de cinamida policiclicos
CO6220853A2 (es) Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios
NO20060247L (no) Substituerte spirobenzazepiner
ATE305454T1 (de) Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten
ATE557019T1 (de) Pyrrolidin-3-ylmethyl-amin als orexin- antagonisten
MX2013004739A (es) Derivados heterociclicos de diazenodiolato.
PT1214323E (pt) Indoloazepinas como antagonistas do receptor de vasopressina
MA32512B1 (fr) Derive de phenanthrenone, compositions et procedes
WO2006049984A3 (en) Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
YU32702A (sh) Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina
MA34462B1 (fr) Composes de thiophene 2,3,5- trisubstitues et leurs utilisations
DE602008003572D1 (de) Organische verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2078022

Country of ref document: EP